HemeMRD Kit

B cell receptor (BCR) sequencing panel is used to detect the rearrangement of human B lymphocyte receptor gene in relative quantitation. The results of this assay mainly assist the diagnosis of ALL, MM and CLL by detecting BCR gene rearrangement, so as to facilitate clinicians to make more accurate assessment and right treatment of patients in combination with other test results. For hematological malignancies, Minimal/measurable/molecule residual disease ( MRD) testing can be used for risk stratification, efficacy assessment, recurrence monitoring, and clonal evolution tracking.

Advantages of HemeMRD Detection

• High sensitivity: Sensitivity as high as 0.0001%

• Broad applications: Suitable for B-ALL, MM and CLL patients

• Detection of new clones: Identifications of clone evolutions, immune recovery, and immune reconstitution

• Excellent repeatability: Standardarizedexperimental process and bioinformatics analysis

Indications of HemeMRD Detection

Applicable disease type

Specimen type

Acute B lymphoblastic leukemia (B-ALL)

Bone marrow or peripheral blood

Multiple myeloma (MM)

Bone marrow or peripheral blood

Chronic lymphocytic leukemia (CLL)

Bone marrow or peripheral blood

Sample Requirements and Sensitivity

Specimen

Volume

Shipping conditions

Before treatment

Bone marrow (fresh)

1mL

4 48h

Peripheral blood (fresh)

2-3mL

4 48h

DNA

2ug

Dry ice , 48h

Specimen

 Volume

Shipping conditions

After treatment

Bone marrow (fresh)

2-3mL

4, 48h

Peripheral blood (fresh)

>5mL

4, 48h

DNA

>7ug

Dry ice, 48h

Sensitivity

DNA Amount (ug)

10-4

2ug

10-5

7ug

10-6

20ug

If you have any of the following needs, feel free to contact us or email us at inquiry@MEDxTMC.net . We will reply within 24 hours.


1. Customized or bulk orders of IVD/CDx products.

2. Get a quote for IVD/CDx products

3. Become our distributor

4. Get customized pharmaceutical service solutions

5.Learn more about our technology and R&D


Show of MEDx by CCTV